A Phase 2 randomized controlled trial of metformin in high-risk idiopathic pulmonary fibrosis

Study Description

A study testing whether metformin can slow lung function decline in people with idiopathic pulmonary fibrosis who are at high risk for worsening disease

Study Details

Registry ID:

NCT07520110

Conditions:

Idiopathic Pulmonary Fibrosis

Phase:

Phase 3

Target Enrollment:

800 participants

Start Date:

September 28, 2026

Age Range:

40–999 years

Healthy Volunteers:

No

Study Locations (15 sites)

• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• University of Massachusetts Chan Medical School
  Worcester, MassachusettsUnited States, United States
• Weill Cornell Medicine
  New York, New YorkUnited States, United States
• Temple University
  Philadelphia, PennsylvaniaUnited States, United States
• Georgetown University Hospital
  Washington D.C., District of ColumbiaUnited States, United States
• University of Michigan
  Ann Arbor, MichiganUnited States, United States
• Northwestern University
  Chicago, IllinoisUnited States, United States
• University of Chicago
  Chicago, IllinoisUnited States, United States
• Michael E. DeBakey VA Medical Center
  Houston, TexasUnited States, United States
• University of Texas Southwestern
  Dallas, TexasUnited States, United States
• Mayo Clinic
  Rochester, MinnesotaUnited States, United States
• University of Colorado Anschutz
  Aurora, ColoradoUnited States, United States
• University of Arizona
  Tucson, ArizonaUnited States, United States
• University of Utah
  Salt Lake City, UtahUnited States, United States
• University of Washington
  Seattle, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →